Regenerative Medicine · Miami, FL
Umbilical Cord Stem Cell Therapy in Miami
Karli Health is led by Harvard-trained physician, researcher and published author David Karli, MD, MBA.
Umbilical cord stem cell therapy is a donor-derived regenerative medicine option using mesenchymal stem cells sourced from Wharton’s jelly within umbilical cord tissue collected after a healthy live birth. At Karli Health, each product is carefully reviewed and the viable cell dose is measured again immediately before treatment so Dr. Karli knows the dose being administered.
The Therapy
What Is Umbilical Cord Stem Cell Therapy?
Umbilical cord stem cell therapy uses donor-derived mesenchymal stem cells from Wharton's Jelly within the umbilical cord tissue. These are considered perinatal, or birthing tissue, sources and are collected after a healthy live birth, with no impact on the mother or baby after delivery.
What Are Umbilical Cord Stem Cells?
The umbilical cord connects the developing baby to the placenta during pregnancy. Our cells are sourced from the Wharton’s Jelly that’s inside the umbilical cord. Certain umbilical cord derived cells, including mesenchymal stem cells, are studied for their ability to renew themselves, support several tissue types, and participate in regenerative signaling.
Umbilical cord stem cells are collected from cord tissue after a healthy live birth, not from an embryo during development.
How Umbilical Cord Stem Cells Differ From Autologous PRP and BMC
PRP and BMC are autologous therapies, meaning they come from the patient’s own body. Umbilical cord stem cell therapy is allogeneic, meaning the cells come from a qualified donor source. That distinction matters for safety, sourcing, screening, consent, and regulatory review.
How Does Karli Health Approach Umbilical Cord Stem Cell Therapy?
Karli Health does not take a one-size-fits-all approach to donor-derived stem cell therapy. The Karli Standard begins with knowing exactly what product is being used, confirming its source, viability and total viable cell dose, then tracking how that dose relates to the patient’s long-term outcome.
With donor-derived cells, those details matter. The product’s source, identity and viability are reviewed before treatment. In our on-site laboratory, Karli Health re-measures cell viability immediately before injection using a mini flow cytometer that counts both living and dead cells. This gives Dr. Karli an immediate, additional confirmation of the actual viable cell dose being administered—not simply the post-thaw viability reported from the original culturing and processing.
Dr. Karli determines the dose and treatment approach based on the patient’s condition, goals and available evidence.
Patient-reported outcomes are tracked through the Greyledge Data Cloud, connecting the dose and treatment protocol with the patient’s reported outcome over time. As that data continues to build, dosing and treatment protocols can be refined.
That’s the Karli Standard in practice: know what was administered, know the dose, and connect it to the patient’s outcome over time.
What Does Current Research Say About Umbilical Cord Stem Cells?
Although the clinical research is still limited, the relevant published studies that do exist have reported encouraging results when UC-MSCs were compared with commonly used orthopedic treatments, including hyaluronic acid injections (“gel shots”) and steroid injections.
For Karli Health and Greyledge Technologies, that is not the end of the story—it is the beginning. Our goal is to better understand which patients respond, what dose they receive, how viable the cells are at the time of treatment, how the product is administered, and which protocols produce the best outcomes.
We believe regenerative medicine should continue moving toward better-measured, better-tracked alternatives that may help reduce patients’ reliance on repeated gel or steroid injections and, where appropriate, help delay or avoid more invasive treatment.
That is why the Karli Standard is built around measuring, treating, tracking and refining—and why Greyledge is actively collecting the data needed to help answer the questions the field is still asking.
Florida Law and Permitted Use
In July 2025, Florida enacted a stem cell law allowing licensed physicians to perform qualifying stem cell therapies related to orthopedics, wound care, or pain management when the treatment is within the physician’s scope of practice and the requirements of Florida law are met.
Karli Health follows Florida state law, including requirements related to product sourcing, manufacturing, storage, viability documentation, patient disclosure that these therapies are not FDA-approved, and signed informed consent.
Stem cell therapy is not appropriate for every patient or condition. Eligibility remains based on diagnosis, medical history, imaging, treatment goals, safety review, physician evaluation, and patient choice.
Safety, Sourcing, and Manufacturing Standards
Umbilical cord stem cell products should come from ethically sourced donor tissue and qualified manufacturing facilities. Karli Health works only with suppliers that meet applicable Florida requirements, including required facility registration, accreditation or certification standards, cGMP requirements, and verified product-specific documentation.
Before treatment, Karli Health reviews the product source, identity, lot-specific documentation, sterility and safety testing, and manufacturer-provided post-thaw viability documentation.
Karli Health then goes one step further. Immediately before treatment, our on-site laboratory measures cell viability again using a mini flow cytometer that counts both living and dead cells, giving Dr. Karli an additional confirmation of the actual viable cell dose being administered; not simply the viability reported by the manufacturer.
What Conditions May Be Evaluated for Umbilical Cord Stem Cell Therapy?
Depending on diagnosis, medical history, imaging and physician evaluation, umbilical cord stem cell therapy may be considered for qualifying orthopedic, wound care and pain-management conditions under Florida law.
Explore Orthopedic Care
What Should Patients Ask Before Umbilical Cord Stem Cell Therapy?
Before considering umbilical cord stem cell therapy, patients should ask where the cells come from, how the donor material was screened, where the product was processed and stored, whether lot-specific post-thaw viability documentation is available, and whether cell viability and the actual viable cell dose are confirmed again immediately before treatment.
Patients should also understand the proposed dose and route of administration, how outcomes will be tracked, and the potential risks, benefits, limitations and alternatives. A complete informed-consent process should occur before treatment.
Patient Eligibility
Umbilical cord stem cell therapy is not appropriate for every patient. Eligibility depends on diagnosis, medical history, prior treatments, imaging, treatment goals, safety review and physician evaluation.
Patient preference also matters. Some patients simply do not want donor stem cells. At Karli Health, we review the pros and cons, what we know, what we do not yet know, and the available treatment options so each patient can make an informed decision.
FAQ
Umbilical cord stem cell therapy is a donor-derived regenerative medicine option using cells sourced from Wharton’s jelly within the umbilical cord after a healthy live birth.
No. It is allogeneic, meaning the cells come from a donor rather than from your own body.
No. Umbilical cord stem cells are collected from cord tissue after a healthy live birth, not from an embryo during development.
At Karli Health, patients may be given simple medications such as Tylenol and Zyrtec before treatment to help reduce the chance of mild reactions. Patients are also monitored during and after treatment.
Florida law permits certain non-FDA-approved stem cell therapies related to orthopedic conditions, wound care, and pain management. Candidacy still requires physician evaluation and must meet the requirements of Florida law.
No. Umbilical cord stem cell therapy is not FDA-approved. However, Florida law allows qualified physicians to perform certain stem cell therapies related to orthopedics, wound care and pain management when the requirements of state law are met. Karli Health follows Florida state law, including required patient disclosure and informed consent.
Related regenerative therapies
PRP Therapy
Platelet-rich plasma prepared from your own blood, measured and dosed in our on-site lab.
Open PRP TherapyBone Marrow Concentrate — BMC
Your own bone marrow cells, concentrated and characterized before treatment.
Open Bone Marrow ConcentrateMUSE Cell Therapy
A distinct donor cell type with published research and tracked patient outcomes.
Open MUSE Cell TherapyLOOK. FEEL. PERFORM GREAT.
Considering Umbilical Cord Stem Cell Therapy?
Schedule a consultation with Karli Health to learn whether umbilical cord stem cell therapy, PRP, BMC, MUSE cell therapy, exosome therapy, or another regenerative option may be appropriate for your condition and goals.
Medically reviewed by David Karli, MD, MBA · Harvard-trained physician, researcher and published author
Last reviewed: September 30, 2026